Skip to main content

and
  1. Article

    Open Access

    Retraction Note: MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer

    This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s12943-017-0615-x.

    Zhuo-yuan Lin, Guo Chen, Yan-qiong Zhang, Hui-chan He, Yu-xiang Liang in Molecular Cancer (2023)

  2. Article

    Open Access

    Correction to: MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer

    After publication of the article [1], the author reported that this article contained some errors.

    Zhuo-yuan Lin, Guo Chen, Yan-qiong Zhang, Hui-chan He, Yu-xiang Liang in Molecular Cancer (2019)

  3. Article

    Open Access

    RETRACTED ARTICLE: MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer

    Even though aberrant expression of microRNA (miR)-30d has been reported in prostate cancer (PCa), its associations with cancer progression remain contradictory. The aim of this study was to investigate clinica...

    Zhuo-yuan Lin, Guo Chen, Yan-qiong Zhang, Hui-chan He, Yu-xiang Liang in Molecular Cancer (2017)

  4. No Access

    Article

    MicroRNA-30c serves as an independent biochemical recurrence predictor and potential tumor suppressor for prostate cancer

    MicroRNA-30c (miR-30c) acts as a tumor suppressor or a tumor promoter in various human malignancies. However, the involvement of miR-30c in prostate cancer (PCa) is still unclear. The aim of this study was to ...

    **ao-hui Ling, Zhao-dong Han, Dan **a, Hui-chan He in Molecular Biology Reports (2014)

  5. No Access

    Article

    Decreased expression of myosin light chain MYL9 in stroma predicts malignant progression and poor biochemical recurrence-free survival in prostate cancer

    The aim of this study was to investigate the associations of myosin light chain (MYL9) downregulation with tumor progression and prognosis in patients with prostate cancer (PCa). MYL9 protein expression in hu...

    Ya-qiang Huang, Zhao-dong Han, Yu-xiang Liang, Zhuo-yuan Lin in Medical Oncology (2013)

  6. Article

    Open Access

    Global analysis of the differentially expressed miRNAs of prostate cancer in Chinese patients

    Our recent study showed the global physiological function of the differentially expressed genes of prostate cancer in Chinese patients was different from that of other non-Chinese populations. microRNA are est...

    Hui-chan He, Zhao-dong Han, Qi-shan Dai, **ao-hui Ling, **n Fu in BMC Genomics (2013)

  7. No Access

    Article

    Down-regulation of the ErbB3 binding protein 1 in human bladder cancer promotes tumor progression and cell proliferation

    The ErbB3 binding protein 1 (Ebp1) represents a downstream effector of the ErbB signaling network and has been demonstrated to be a potent tumor suppressor in various human malignancies, however, its involveme...

    Hui-chan He, **ao-hui Ling, Jian-guo Zhu, **n Fu in Molecular Biology Reports (2013)

  8. No Access

    Article

    Analysis of genetic aberrations on chromosomal region 8q21–24 identifies E2F5 as an oncogene with copy number gain in prostate cancer

    The copy number gain of genes in chromosomal region 8q21–24 has been demonstrated to be associated with genesis and progression of prostate cancer (PCa). The aim of this study was to identify novel and effecti...

    ** Zhao, **n-yang Wu, **ao-hui Ling, Zhuo-yuan Lin, **n Fu in Medical Oncology (2013)

  9. Article

    Open Access

    SOXs in human prostate cancer: implication as progression and prognosis factors

    SOX genes play an important role in a number of developmental processes. Potential roles of SOXs have been demonstrated in various neoplastic tissues as tumor suppressors or promoters depending on tumor status...

    Wei-de Zhong, Guo-qiang Qin, Qi-shan Dai, Zhao-dong Han, Shan-ming Chen in BMC Cancer (2012)